logo
Remembering Tom Reilley: Father, husband, and the face of a Hilton Head restaurant empire

Remembering Tom Reilley: Father, husband, and the face of a Hilton Head restaurant empire

Yahoo11-05-2025
It's almost five o'clock at Reilley's Grill and Bar on Hilton Head Island, and the long mahogany bar is already filled with silver-haired patrons enjoying a happy hour drink. Most of the tables in the restaurant are unusually empty; the rain is coming down hard outside, keeping most of the usual crowd of locals at home. But there's one more person missing from the scene who will never take his usual spot at the corner of the bar again.
Thomas Reilley, iconic Hilton Head restauranteur best known for founding Coastal Restaurants and Bars, passed away on May 2, after battling severe health problems for nearly three months. He celebrated his 78th birthday in the hospital in April.
His death marks the third loss of a major personality for the island this year — entrepreneurs and leaders in the food, beverage and hospitality industry who left their marks on locals' hearts through the connections they made.
The story of Reilley's Grill and Bar is a classic tale of Hilton Head Island: a young couple leaves behind their snowy hometowns in search of opportunity on a small island on the onset of becoming one of the biggest tourist destinations on the Atlantic coast. The Reilley family came to be more than the owners of a couple of successful restaurants — like others who established roots on the island in the early days, Tom's legacy is woven deep into the fabric of the town's history.
Tom was born in Providence, Rhode Island to an Irish father and an Italian mother. The oldest of eight siblings in a family that didn't have much money, Tom took on leadership and responsibility at a young age. He was protective of his younger siblings — taking his sisters to school dances when no one else could, keeping a close eye on who they were getting into cars with.
The future entrepreneur worked nearly all his life, starting out at his grandfather's marble and tile company from the age of 12 or 13. He spent years climbing the ladder in the food and beverage industry, often hiring his siblings to work underneath him. Tom's father, a realtor who at one time also owned a bar, passed down a valuable piece of wisdom to his children:
''Don't ever work like an employee,'' sister Michaela Simmons recalls her father saying. ''Work like an owner.''
Their family moved to Warwick, Rhode Island, when Tom's sister Patti Culton was a young girl. She recounted fond memories of playing with the neighborhood kids during the daytime but coming home when the street lights came on. Every evening, the whole family would come together for dinner and talk about what happened during the day and who said what to whom.
'Our whole childhood revolved around the kitchen table,' Culton said.
When Tom opened his first restaurant, his father told him to treat the restaurant 'like the kitchen table.' And he did, his sister said, carrying on the tradition of making people feel seen and heard and valued the moment they walked in the door.
'All I could think of when he passed away was that feeling like somebody had shut the kitchen lights off,' Culton said.
One evening in February 1977, Tom hopped in his Ford Torino and picked up his now-wife Diane, who thought he was taking her to go see the recently released film Rocky. Instead, he changed the course of their lives.
'He got on 95 the other way,' Diane recalled. 'I said, 'Where the heck are you going?' He said, 'South Carolina.''
They made the 18-hour journey from Boston down to Hilton Head Island, a place that had one traffic light and no big grocery store, and ended up staying. In the start, they lived with Tom's sisters Mary and her husband. Diane picked up at job at the the Calibogue Seafood House in Harbour Town, in a building that now houses the Crazy Crab; Tom started off at the Hyatt Regency as a manager in the banquet department.
It would be a few years before Tom and Diane got the opportunity to open their first restaurant: the original Reilley's, established in 1982. That building no longer exists; a fire in 1995 prompted the family to move the current location across the street, and the restaurant was remodeled in 2004. But the spirit of the Reilley's stayed the same: a place where Tom knew everybody's name and treated customers like family.
'Like Cheers,' Diane said.
Life with seven children got chaotic at time. The Reilley kids spent their youth running wild around a version of Hilton Head Island that's much different than the world their children will grow up in, a world where everybody knew everybody and neighbors watched over each others' kids. They'd run in and out of the nearby shops and restaurants: a boutique clothing store called The Porcupine, Curry Dry Cleaners, and restaurant down the road called Julep's, none of which are still standing on the island.
Tom was a man of routine up into his final years. Every morning at nine o'clock, he'd walk in to the restaurant to count the money from the night before, watching golf on the TV and chatting about with restaurant manager Kiel Phillips as he opened the bar. He had lunch every day with his son Jeff, and popped in for happy hour every evening to greet the regulars and enjoy his favorite drink: a glass of red wine over ice.
He worked seven days a week, and practically lived in his office. Back in the old days, his office was crammed into a small, nondescript room not much bigger than a storage closet. At five o'clock, he'd walk next door to what was called 'the boardroom' — a private, a dimly lit 'guy's club' where Tom and his buddies played darts and gin rummy. Kids weren't allowed, but sometimes son Thomas would steal a key and sneak in with his friends.
That's how things were until 2011. 'Then the group of guys just got a little small,' the son remarked. He and his brother Brendan transformed the place into a bar and music venue, and Tom moved to a nearby office in the same plaza.
As Tom got older, adult children began to take over the family company. Brendan has been the key driver in the company's growth in recent years, and has opened new restaurants with his brothers Thomas and Keith. His oldest daughter Erin Booth, who worked with him for 26 years, is now managing partner of Reilley's Grill and Bar along with her husband Jaime Booth. Catherine joined the group in 2021 after burning out from a long career worked in marketing for firms in New York, Chicago, and Boston. Jeff works as a real estate attorney, but owns a minority stake in some of the family's restaurants. 'Free-spirited' Jenna, the youngest of the bunch, is the only one not involved in the business, and lives in Colorado.
Tom's family extended beyond his seven children, son Thomas remarked.
The doors of the Reilley family home were always open. The kids' friends would come in and out, frequently spending the night. It wasn't uncommon for there to be twenty extra people in the house on the weekend. Tom and Diane also took in a handful of people not just friends and family, but anyone who needed a safe space to call home. Two of Tom's 'adopted' children were there by his bedside when he passed away.
One Monday morning in early February, Tom drove himself to Reilley's after going to a regular doctor's appointment, where he was told he had an irregular heartbeat. As he tallied the receipts like he did every morning, Tom started to feel very unwell.
Erin, who has worked alongside her father for 26 years, remembers sitting in her office when Tom called her to drive her home. She and her husband Jaime took him home and returned to the office to carry on with work. Less than 30 minutes after, Erin got another call from Tom.
'He said, 'I think I need to go to the hospital,'' said Erin.
An ambulance took Tom to Hilton Head Medical. Tom's wife Diane was in Jamaica at the time on a missionary trip. When she got back, she and Erin drove two hours north to the Medical University of South Carolina, where he stayed for two months.
He never really got better.
Tom's family made the difficult decision to transfer him to hospice care, after watching him battle his illnesses for nearly three months. He died surrounded by his wife, children, grandchildren, siblings, and cousins.
Most of Tom's family members were able to hold back tears as they spoke about the father, husband, or brother that they loved and admired so deeply. Erin, Tom's oldest daughter, broke down in tears almost immediately when asked to recall the man who was not just her father, but also her best friend.
'He had so much wisdom,' Erin said tearfully. 'He cared deeply. He really loved everybody and saw the positive in everybody ... I always knew that he was somebody that I could come to and I could rely on.'
The walls of Tom's office are coated in dozens of framed photographs and memorabilia. Sitting at his desk, Tom would have been surrounded by memories of weddings, family vacations, beach photo shoots, brothers and sisters, children and grandchildren all smiling from the walls. Taped to the left side of his computer monitor, alongside scribbled notes and reminders, is a printed photograph Erin and her husband Jamie.
The future of Coastal Restaurants and Bars is now in the hands of the surviving Reilley children, who admit they're not quite as outgoing as their father was. His personality, showmanship, and the ease at which he was able to connect with people made him a foundational piece of the restaurant empire that the family will never be able to replace.
'You don't have to know who owns Benny's,' son Thomas remarked, referring one of the family's more recent business ventures. 'Reilley's survived because Tom Reilley was there, and thrived.'
A funeral service for Thomas Reilley is schedule for May 13 at 1:00 p.m., at the Holy Family Catholic Church at 24 Pope Ave.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Natuzzi Announces Appointment of Non-Executive Director
Natuzzi Announces Appointment of Non-Executive Director

Business Wire

time34 minutes ago

  • Business Wire

Natuzzi Announces Appointment of Non-Executive Director

SANTERAMO IN COLLE, Bari, Italy--(BUSINESS WIRE)--Natuzzi S.p.A. (NYSE: NTZ) ('Natuzzi' or the 'Company') announced today that Mr. Pietro Labriola has formally accepted the appointment as a non-executive director of the Company by way of co-optation, effective August 6, 2025, further to the resolution adopted by the Board of Directors on July 29, 2025. Mr. Labriola will remain in office until the next Shareholders' Meeting, at which time it will be submitted for confirmation by the shareholders. Mr. Labriola currently serves as Chief Executive Officer and General Manager of Telecom Italia S.p.A. (TIM), one of the leading telecommunications companies in Europe. He has over 30 years of experience in the telecom and technology sectors, having held senior executive positions in both Italy and abroad, including as CEO of TIM Brazil. He holds a degree in Business and Economics from the University of Bari and a Master in Management of Innovation and Technologies from Tecnopolis, the Scientific and Technological Park of Bari. He is a member of the board of GSMA, the organization that brings together mobile network operators worldwide, and a member of the General Council of Confindustria, the main representative association of manufacturing enterprises and services in Italy, where, since May 2024, he has the mandate for the Digital Transition. He is also President of Asstel, the Italian trade association within Confindustria that represents the telecommunication sector. In the TIM Group since 2001, he has held increasingly senior roles in the field of Marketing for the corporate and consumer segments in both fixed and mobile telephony services. Before joining TIM, he worked at Infostrada, then Boston Consulting Group, Cable&Wireless, and France Telecom. The Board of Directors believes that Mr. Labriola's extensive international executive experience and deep knowledge of innovative technologies and services, combined with its strategic vision and operational expertise, will contribute to driving the Company's digital transformation and sustainable growth. ***** CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS Certain statements included in this press release constitute forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be expressed in a variety of ways, including the use of future or present tense language. Words such as 'estimate,' 'forecast,' 'project,' 'anticipate,' 'likely,' 'target,' 'expect,' 'intend,' 'continue,' 'seek,' 'believe,' 'plan,' 'goal,' 'could,' 'should,' 'would,' 'may,' 'might,' 'will,' 'strategy,' 'synergies,' 'opportunities,' 'trends,' 'ambition,' 'objective,' 'aim,' 'future,' 'potentially,' 'outlook' and words of similar meaning may signify forward-looking statements. These statements involve inherent risks and uncertainties, as well as other factors that may be beyond our control. The Company cautions readers that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Such factors include, but are not limited to: effects on the Group from competition with other furniture producers, material changes in consumer demand or preferences, significant economic developments in the Group's primary markets, the Group's execution of its reorganization plans for its manufacturing facilities, significant changes in labor, material and other costs affecting the construction of new plants, significant changes in the costs of principal raw materials and in energy costs, significant exchange rate movements or changes in the Group's legal and regulatory environment, including developments related to the Italian Government's investment incentive or similar programs, the duration, severity and geographic spread of any public health outbreaks (including the spread of any future epidemic), consumer demand, our supply chain and the Company's financial condition, business operations and liquidity, the geopolitical tensions and market uncertainties resulting from the ongoing armed conflict between Russia and Ukraine, the Israel-Hamas war and other conflicts in the Middle East, the inflationary environment and potential increases in interest rates and energy prices, as well as protectionist trade policies, tariffs and related retaliatory measures. The Company cautions readers that the foregoing list of important factors is not exhaustive. When relying on forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and events. Additional information about potential factors that could affect the Company's business and financial results is included in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's most recent Annual Report on Form 20-F. The Company undertakes no obligation to update any of the forward-looking statements after the date of this press release. About Natuzzi S.p.A. Founded in 1959 by Pasquale Natuzzi, Natuzzi S.p.A. is one of the most renowned brands in the production and distribution of design and luxury furniture. As of March 31, 2025, Natuzzi distributes its collections worldwide through a global retail network of 610 monobrand stores in addition to galleries. Natuzzi products embed the finest spirit of Italian design and the unique craftsmanship details of the 'Made in Italy', where a predominant part of its production takes place. Natuzzi has been listed on the New York Stock Exchange since May 13, 1993. Committed to social responsibility and environmental sustainability, Natuzzi S.p.A. is ISO 9001 and 14001 certified (Quality and Environment), ISO 45001 certified (Safety on the Workplace) and FSC ® Chain of Custody, CoC (FSC-C131540).

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Associated Press

time35 minutes ago

  • Associated Press

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

Yahoo

time2 hours ago

  • Yahoo

Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election

Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election. Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period. ORLANDO, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed by the Election will take place over the course of September and October. During this period, Co-Founder and Chairman, Serguei Melnik will take over the responsibilities of CEO and guide the company through the final 2025 framework towards the target NDA filing in 2026. Mr. Melnik, a corporate strategy expert will continue to execute the Company's strategic development and focus on shareholder value. Mr. Melnik has over 20 years experience in Capital markets. "I have made the decision to temporarily step aside as CEO following the support and encouragement I have received asking me to put my name forward for the election for President of Ireland. Rest assured, Nutriband is in very safe hands. While most often we talk about AVERSA as our big opportunity, it is our tight knit team that is really our core asset. I look forward to watching Nutriband continue to hit its planned targets between now and December," said Mr. Sheridan. The FDA recently granted Nutriband's meeting request for AVERSA Fentanyl AVERSA FENTANYL has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA FENTANYL has the potential to reach peak annual US sales of $80 million to $200 million.1 While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and our goal is to make AVERSA FENTANYL available in all major medical markets in the world. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ____________________________________________________1 Health Advances Aversa Fentanyl market analysis report 2022 About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is Any material contained in or derived from the Company's websites or any other website is not part of this press release. Forward-Looking Statements Certain statements contained in this press release, including, without limitation, statements containing the words ''believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Contact Information: Nutriband 407-377-6695Email: info@ SOURCE: Nutriband in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store